Companies
Eli Lilly and Company
Articles
SIG-005: Novel Encapsulated Non-Viral ...

SIG-005: Novel Encapsulated Non-Viral Cell-Based Therapy for MPS-1

Jun. 30, 2021- By: Marissa Donovan;Erika Pearson;Drew Tietz;Elizabeth Do;Lauren Jansen;Chris Sparages;Michele McAuliffe;Tiffany Vo;Lauren Sohn;Elina Makino

Courtesy ofEli Lilly and Company

HYPOTHESIS: sustained therapeutic effect could be achieved by administration of IDUA-secreting allogeneic human cells shielded within spheres designed to avoid immune rejection and pericapsular fibrotic overgrowth (PFO)

SIG-005: Novel Encapsulated Non-Viral Cell-Based Therapy for MPS-1

Contact supplier